Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mixed Results For China’s First Home-Grown COVID Antiviral

Russia Trial Meets Endpoints

Executive Summary

A preliminary analysis of Russian Phase III results for azvudine, China's first home-grown antiviral for COVID-19, shows it reached two primary endpoints, but a separate Chinese study produced mixed results.

You may also be interested in...



Chinese-Language Podcast: 聊聊七月生物制药热门话题

Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector. 

RNAi Developer Sirnaomics Targets Untapped Oncology Indications In China

The US- and China-based biotech is expanding three oncology-centered clinical studies of two TGF-1/COX-2-targeted siRNA drug candidates from the US into China.

Chinese Biotechs Feel Chill Wind Of Hesitant Investors

Large or small, Chinese biotechs are receiving the cold shoulder from some investors amid souring investment sentiment. HanBio, Frontier and InnoCare have all seen their fundraising efforts hampered to various degrees.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel